PMID- 32343486
OWN - NLM
STAT- MEDLINE
DCOM- 20210105
LR  - 20210105
IS  - 1751-553X (Electronic)
IS  - 1751-5521 (Linking)
VI  - 42
IP  - 4
DP  - 2020 Aug
TI  - Lymphocyte-monocyte ratio (LMR) can predict bendamustine therapeutic efficacy in 
      low-grade B-cell lymphoma.
PG  - 431-438
LID - 10.1111/ijlh.13216 [doi]
AB  - INTRODUCTION: Bendamustine has been reported to be effective against low-grade 
      B-cell lymphoma. We examined the effect of bendamustine on the 
      lymphocyte-monocyte ratio (LMR) in low-grade B-cell lymphoma patients. METHODS: 
      We retrospectively reviewed 127 cases of first line or relapse/refractory 
      low-grade B-cell lymphoma in three individual institutions (Asahikawa Municipal 
      Hospital, Aiiku Hospital, and Hakodate Municipal Hospital). Only patients who had 
      received at least three courses of bendamustine therapy were selected; the LMR 
      was evaluated at starting the initial course of bendamustine therapy. Time to 
      next treatment (TTNT) was used to ascertain the efficacy of bendamustine therapy. 
      RESULTS: Follicular lymphoma (FL), at 68.5% (87/127), is the most common 
      histological subtype of low-grade B-cell lymphoma. The receiver operating 
      characteristic (ROC) curve for the LMR showed a cutoff value of 2.0, and 33 cases 
      (26.0%) had an LMR </=2.0. Cases with LMR </=2.0 had a significantly earlier 
      progression than those with LMR > 2.0, based on the TTNT (P = .0007). 
      Additionally, LMR </=2.0 indicates earlier progression in TTNT when comparing only 
      FL and low-grade B-cell lymphoma cases without FL (P = .007, 0.002). For 
      multivariate analysis, the factors associated with an LMR </=2.0 (HR, 2.741; 95% 
      CI, 1.4330-5.245; P = .002) were considered as early progression factors with 
      regard to the TTNT. CONCLUSION: Lymphocyte-monocyte ratio effectively predicts 
      the efficacy of bendamustine therapy for low-grade B-cell lymphoma, particularly 
      FL; its application may improve treatment strategies for this disease.
CI  - (c) 2020 John Wiley & Sons Ltd.
FAU - Shimono, Joji
AU  - Shimono J
AUID- ORCID: 0000-0003-1044-1654
AD  - Department of Hematology, Asahikawa Municipal Hospital, Asahikawa, Japan.
AD  - Department of Hematology, Graduate School of Medicine, Hokkaido University 
      Faculty of Medicine, Sapporo, Japan.
FAU - Izumiyama, Koh
AU  - Izumiyama K
AD  - Blood Disorders Center, Aiiku Hospital, Sapporo, Japan.
FAU - Ito, Shinichi
AU  - Ito S
AD  - Department of Hematology, Hakodate Municipal Hospital, Hakodate, Japan.
FAU - Tsutsmi, Yutaka
AU  - Tsutsmi Y
AD  - Department of Hematology, Hakodate Municipal Hospital, Hakodate, Japan.
FAU - Kondo, Takeshi
AU  - Kondo T
AD  - Blood Disorders Center, Aiiku Hospital, Sapporo, Japan.
FAU - Kakinoki, Yasutaka
AU  - Kakinoki Y
AD  - Department of Hematology, Asahikawa Municipal Hospital, Asahikawa, Japan.
FAU - Teshima, Takanori
AU  - Teshima T
AD  - Department of Hematology, Graduate School of Medicine, Hokkaido University 
      Faculty of Medicine, Sapporo, Japan.
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Multicenter Study
DEP - 20200428
PL  - England
TA  - Int J Lab Hematol
JT  - International journal of laboratory hematology
JID - 101300213
RN  - 981Y8SX18M (Bendamustine Hydrochloride)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Bendamustine Hydrochloride/*administration & dosage
MH  - Female
MH  - Humans
MH  - Lymphocyte Count
MH  - *Lymphocytes/metabolism/pathology
MH  - *Lymphoma, B-Cell/blood/drug therapy/pathology
MH  - *Lymphoma, Follicular/blood/drug therapy/pathology
MH  - Male
MH  - Middle Aged
MH  - *Monocytes/metabolism/pathology
MH  - Recurrence
MH  - Retrospective Studies
OTO - NOTNLM
OT  - bendamustine
OT  - lmr
OT  - low-grade B-cell lymphoma
OT  - malignant lymphoma
EDAT- 2020/04/29 06:00
MHDA- 2021/01/06 06:00
CRDT- 2020/04/29 06:00
PHST- 2020/02/19 00:00 [received]
PHST- 2020/03/24 00:00 [revised]
PHST- 2020/04/06 00:00 [accepted]
PHST- 2020/04/29 06:00 [pubmed]
PHST- 2021/01/06 06:00 [medline]
PHST- 2020/04/29 06:00 [entrez]
AID - 10.1111/ijlh.13216 [doi]
PST - ppublish
SO  - Int J Lab Hematol. 2020 Aug;42(4):431-438. doi: 10.1111/ijlh.13216. Epub 2020 Apr 
      28.